tivozanib (Fotivda, AV-951)
Jump to navigation
Jump to search
Indications
- metastatic renal cell carcinoma (FDA-approved March 2021)
Dosage
- 1.5 mg daily, 3 weeks on & 1 week off
Pharmacokinetics
- long 1/2 life
Adverse effects
- > 20%
- laboratory abnormalities > 5%
- hyponatremia, increased serum lipase, hypophosphatemia[3]
Mechanism of action
- inhibits VEGF1, VEGF2 & VEGF3
More general terms
References
- ↑ Nosov DA el al Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma J Clin Oncol. 2012 May 10;30(14):1678-85 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22493422 <Internet> http://jco.ascopubs.org/content/30/14/1678
- ↑ Journal Watch: Aging/Geriatrics July 2, 2012 ASCO 2012 Report: Genitourinary Cancer Massachesetts Medical Society http://oncology-hematology.jwatch.org
- ↑ 3.0 3.1 Bankhead C FDA Approves Tivozanib for Late-Line Renal Cell Carcinoma - First treatment to improve PFS after two or three prior lines of therapy. MedPage Today March 11, 2021 https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/91582